MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413297 | Name: Stibophen

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Stibophen is an anthelmintic classified as antimony compound and used as treatment of schistosomiasis by intramuscular injection.

Chemical Structure

Stibophen
Stibophen
CAS#15489-16-4

Theoretical Analysis

MedKoo Cat#: 413297

Name: Stibophen

CAS#: 15489-16-4

Chemical Formula: C12H18Na5O23S4Sb

Exact Mass: 893.7648

Molecular Weight: 895.20

Elemental Analysis: C, 16.10; H, 2.03; Na, 12.84; O, 41.11; S, 14.33; Sb, 13.60

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Stibophen; SDT91; SDT-91; SDT 91
IUPAC/Chemical Name
sodium 2-(2-oxido-3,5-disulfonatophenoxy)benzo[d][1,3,2]dioxastibole-4,6-disulfonate heptahydrate
InChi Key
ZDDUXABBRATYFS-UHFFFAOYSA-F
InChi Code
InChI=1S/2C6H6O8S2.5Na.7H2O.Sb/c2*7-4-1-3(15(9,10)11)2-5(6(4)8)16(12,13)14;;;;;;;;;;;;;/h2*1-2,7-8H,(H,9,10,11)(H,12,13,14);;;;;;7*1H2;/q;;5*+1;;;;;;;;+3/p-8
SMILES Code
[O-]c1c(S(=O)([O-])=O)cc(S(=O)([O-])=O)cc1O[Sb]2Oc3c(O2)c(S(=O)([O-])=O)cc(S(=O)([O-])=O)c3.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
Soluble in DMSO 0.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 895.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: STIBOPHEN. Bull Am Pharm Assoc. 1946 Jan-Feb;14:39. PMID: 21013035. 2: Katz M. Anthelmintics. Drugs. 1977 Feb;13(2):124-36. doi: 10.2165/00003495-197713020-00002. PMID: 319991. 3: DETORREGROSA MV, RODRIGUEZROSADO AL, MONTILLA E. HEMOLYTIC ANEMIA SECONDARY TO STIBOPHEN THERAPY. JAMA. 1963 Nov 9;186:598-9. PMID: 14059041. 4: KAHN HR, BROD RC. Thrombocytopenia due to stibophen. Arch Intern Med. 1961 Sep;108:496-501. doi: 10.1001/archinte.1961.03620090168018. PMID: 13750744. 5: Saz HJ, Dunbar GA. The effects of stibophen on phosphofructokinases and aldolases of adult filariids. J Parasitol. 1975 Oct;61(5):794-801. PMID: 171364. 6: Goodwin LG. A note on the fate of stibophen in the body. Biochem J. 1943 Oct;37(4):482-3. doi: 10.1042/bj0370482. PMID: 16747676; PMCID: PMC1257945. 7: Girgla HS, Marsden RA, Singh GM, Ryan TJ. Post-kala-azar dermal leishmaniasis. Br J Dermatol. 1977 Sep;97(3):307-11. doi: 10.1111/j.1365-2133.1977.tb15188.x. PMID: 921902. 8: HALAWANI A, DAWOOD MM. Evaluation of the treatment of bilharziasis with fouadin, stibophen and anthiomaline with special reference to the apparent cure- rates and relapse-rates. J Egypt Med Assoc. 1953;36(5-6):339-56. PMID: 13084832. 9: Weiss HJ, Berger RE, Tice AD, Phillips LL. Fatal disseminated intravascular coagulation and hemolytic anemia following stibophen therapy: a study of basic mechanisms. Am J Med Sci. 1972 Nov;264(5):375-84. doi: 10.1097/00000441-197211000-00005. PMID: 4346511. 10: MILLER MJ, LYON HP. Treatment of vesical schistosomiasis with stibophen. Am J Trop Med Hyg. 1955 Nov;4(6):1049-56. doi: 10.4269/ajtmh.1955.4.1049. PMID: 13268811.